Vitema Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vitema Pharmaceuticals is a private contract manufacturer founded in 2016, headquartered in Vienna, Austria, with its primary operational facility in Sibiu, Romania. The company positions itself as a large-scale, technology-driven CDMO with high automation, boasting an annual capacity of 3.5 billion tablets and capsules. While its website mentions a focus on infectious diseases and vaccines, the detailed content heavily emphasizes its services in manufacturing oral solids, powders, and injectables for pharmaceuticals and nutraceuticals, suggesting its primary revenue is derived from contract services rather than proprietary drug development.

Infectious DiseaseVaccines

Technology Platform

Large-scale, automated, integrated pharmaceutical manufacturing platform for oral solid dosage forms (tablets, capsules) and injectables (vials, syringes). Emphasizes in-house, end-to-end production from testing to packaging.

Opportunities

Capitalizing on the growing global trend of pharmaceutical outsourcing (CDMO model) by leveraging its large-scale, EU-GMP certified manufacturing capacity.

Opportunity to establish long-term strategic supply agreements with nutraceutical and generic pharmaceutical companies seeking reliable, high-volume production.

Risk Factors

Faces intense competition in the crowded CDMO market, which pressures pricing and margins.

Strategic focus appears split between service-based manufacturing and aspirational proprietary R&D, risking resource misallocation.

Operational risks are inherent in running a large, capital-intensive production facility dependent on continuous client contracts.

Competitive Landscape

Operates in the highly competitive European CDMO space, competing against large global players (e.g., Lonza, Catalent) and numerous regional specialists. Its differentiation is based on claimed scale, automation, and cost-effectiveness in oral solid dose manufacturing, rather than proprietary technology. In its stated sectors of Infectious Disease/Vaccines, it is not a visible competitor against clinical-stage biotechs or large vaccine developers.

More companies in Europe - Other →